India’s pharmaceutical sector appears relatively shielded from the latest tariff action announced by the Donald Trump, thanks to its stronghold in low-cost generic medicines.

A recent analysis by the Global Trade Research Initiative (GTRI) suggests that India’s dominance in generic drug exports has helped it avoid major disruption, even as the United States moves to impose steep duties on certain high-value pharmaceutical imports.

What the US Tariff Decision Means

On April 2, the US administration announced 100% tariffs on selected patented medicines and related pharmaceutical ingredients. The move is aimed at reshaping pharmaceutical trade and reducing dependence on high-cost imports.

However, the impact varies significantly across countries and product categories.

Why India Is Largely Safe

India’s pharmaceutical exports are heavily focused on generic medicines—affordable versions of branded drugs whose patents have expired.

Key reasons for India’s protection:

• Generic drugs currently remain outside the tariff scope
• India is a leading supplier of low-cost medicines to the US
• The country plays a crucial role in maintaining affordable healthcare in global markets

According to GTRI, generics account for over 90% of medicines consumed in the United States, making them essential to the healthcare system.

Strong Export Numbers Highlight India’s Position

The data further underlines India’s importance in the global pharma supply chain:

• India exported $9.7 billion worth of medicines to the US in 2025
• This accounted for 38% of India’s total pharmaceutical exports
• Overall global pharma exports stood at $25.8 billion

These figures reinforce India’s reputation as the “pharmacy of the world.”

Potential Risks Still Remain

While the current tariff structure spares generics, experts warn that risks could emerge if policies change.

Ajay Srivastava noted that:

• Indian firms involved in patented or specialty drugs may face pressure
• Suppliers of raw materials linked to patented medicines could also be impacted
• Any future extension of tariffs to generic drugs would significantly alter the scenario

Countries Likely to Be Hit Hard

The tariff decision is expected to affect nations that dominate exports of patented and high-value drugs to the US, including:

• Ireland
• Germany
• Switzerland
• Belgium
• Denmark
• United Kingdom
• Japan

These countries are major exporters of branded and patented pharmaceuticals, making them more vulnerable to the new tariff regime.

Bigger Picture: Shift in Global Pharma Trade

The move by the US signals a broader shift in global pharmaceutical trade policies. It highlights growing efforts to:

• Reduce reliance on expensive imports
• Encourage domestic production
• Restructure global supply chains

For India, this shift presents both an opportunity and a challenge.